Monitoring the Physical Health of Patients on Long-term Antipsychotics - How Easy Will It Be?

Mental Health Review Journal

Volumn 12, Issue 2, 2007, Pages 36-39

  Ahmad, Kauser ^a   Sadiq, Fareeha ^a   Bouch, Joe ^a  

^a GARTNAVEL ROYAL HOSPITAL   (United Kingdom)

Author keywords

Health checks; Long term antipsychotics; Physical health; Severe mental illness

Indexed keywords

EID: 84992944126     PISSN: 13619322     EISSN: None     Source Type: Journal    
DOI: 10.1108/13619322200700020     Document Type: Review

References (14)

1. Alison DB, Mentore JL, Heo M et al (1999) Antipsychoticinduced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156 1689-1696.
2. American Diabetes Association, American Psychiatric Association, The American Association of Clinical Endocrinologist et al (2004) Consensus development conference on antipsychotic drugs, obesity and diabetes. Diabetes Care 27 (2) 596-601.
3. Barr W (2001) Adequate staffing and shared commitment are needed (letter). British Medical Journal 323 231.
4. Bergman RN & Ader M (2005) Atypical antipsychotics and glucose homeostasis. Journal of Clinical Psychiatry 66 (4) 504-514.
5. Citrome L & Yeomans D (2005) Do guidelines for severe mental illness promote physical health and well-being? Journal of Psychopharmacology 19 (6) Supplement 102-110.
6. Department of Health (2004) Choosing Health: Making Healthier Choices Easier. London: Department of Health.
7. Expert Consensus Meeting, Dublin, 14-15 April 2005, Consensus Summary (2005) Metabolic and lifestyle issues and severe mental illness - new connections to well-being? Journal of Psychopharmacology 19 (6) Supplement 118-122.
8. British Society for Disability and Oral Health (2000) Guidelines: Oral Health Care for People with Mental Health Problems. Oxford: BSDOH.
9. Harrison B (2004) Nursing considerations in psychotropic medication-induced weight gain. Clinical Nurse Specialist 18 (2) 80-87.
10. McCreadie RG, Scottish Schizophrenia Lifestyle Group (2003) Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. British Journal of Psychiatry 183 534-539.
11. McIntyre RS, McCann SM & Kennedy SH (2001) Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Canadian Journal of Psychiatry - Revue Canadiene de Psychiatry 46 (3) 273-281.
12. Newcomer JW (2004) Metabolic risk during antipsychotic treatment. Clinical Therapeutics 26 (12) 1936-1946.
13. Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. The American Journal of Psychiatry 160 284-289.
14. Taylor D, Paton, C & Kervin R (2003) The Maudsley 2003 Prescribing Guidelines (seventh edition). London: Martin Dunitz.